Bicycle Therapeutics Ltd (BCYC) Stock Analysis

Bicycle Therapeutics Ltd (BCYC) is a publicly traded company in the HEALTHCARE sector. It trades at $4.18, carries a market capitalization of $291.81M. This page summarizes the public market data, fundamentals, and frequently asked questions for BCYC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Price: $4.18
Market Cap: $291.81M
EPS: $-3.07
52-Week High: $9.18
52-Week Low: $3.92

Market Sentiment

Bicycle Therapeutics Ltd currently has a Neutral sentiment score of -0.05.

About Bicycle Therapeutics Ltd

Bicycle Therapeutics Ltd (BCYC) is an innovative clinical-stage biopharmaceutical company headquartered in Cambridge, UK, specializing in the development of novel therapeutics utilizing its proprietary bicyclic peptide platform. Targeting significant unmet medical needs across various disease areas, particularly in oncology, Bicycle aims to revolutionize treatment modalities with its distinct approach to drug design. The company boasts a robust pipeline of candidates, underscoring its commitm...

GNG Research Analysis

GNG Research scores Bicycle Therapeutics Ltd (BCYC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BCYC.

Frequently Asked Questions

Does BCYC pay dividends?

Bicycle Therapeutics Ltd (BCYC) does not currently pay a regular dividend.

What is BCYC's market cap?

Bicycle Therapeutics Ltd (BCYC) has a market capitalization of $291.81M with a current stock price of $4.18.